Introduction
Vulvovaginal candidiasis is caused by an overgrowth of Candida yeast species in the vagina and is characterized by curd like vaginal discharge, itching, and erythema. Vulvovaginal candidiasis has been associated with considerable direct and indirect economic costs, enhanced susceptibility to HIV infection and is being investigated for a potential relationship with preterm birth. Treatment of vulvovaginal candidiasis is warranted when a woman presenting with a complaint of symptoms consistent with vulvovaginal candidiasis also has laboratory confirmation of the presence of Candida from a vaginal specimen. Short-course azole-based treatment regimens are considered effective and safe and are accessible and affordable in most settings 1 .
Vaginal discharge is a common presenting symptom among the females attending the dermatology outpatient clinic. It represents a major public health problem but many women bear it silently. Reasons for not seeking medical advice can be innumerably ranging from social stigma, hesitation, ignorance and illiteracy. As a result of this stigma and shame, many of these females resort to self-medication. Its impact on mental health and in-terference with routine activities is a matter of concern and hence need to be dealt properly 2 .
Materials and Methods
This cross-sectional descriptive study was conducted at CMH Ghatail during the period of April 2017 to October 2017. Identification: Yeast colonies in the culture were identified by colony morphology, Gram's staining and Germ tube formation for Candida species.
Germ tube test: For Germ tube test, 500 μl of human serum was pipetted into a small test tube. Using a sterile wire loop, a yeast colony from the SDA plate was inoculated. The tube was incubated at 35-37ºC for 2-3 hours. Using the Pasteur pipette, a drop of serum yeast culture was transferred to a glass slide and covered with a cover glass. Tube-like outgrowths from the cells were examined using the 10X and 40X objectives.
Results
Out of 183 HVS processed, only 57(31.15%) specimens were positive for VVC and no Candida species was found in 126 (68.85%) specimens. All the patients had the history of vaginal discharge and many of them have one or more symptoms of vaginal itching, irritation, erythema, burning sensation and dysuria (Table-I) . 
Conclusion
This study provides valuable information regarding prevalence, age distribution, the risk of IUD and commonest Candida species involved in Vulvovaginal Candidiasis. The Candida albicans is the predominant organism isolated from VVC. The high prevalence rates necessitate adequate screening of women with vaginal discharge in order to give appropriate treatment and to avoid risks such as VVC related morbidity in pregnancy which can cause abortion, candida chorioamnionitis, subsequent preterm delivery, emotional stress and enhanced susceptibility to HIV infection.
